Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K
RNA Interference01:23

RNA Interference

27.7K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.7K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

4.2K
4.2K
MicroRNAs01:22

MicroRNAs

3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs01:22

MicroRNAs

23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Multi-Antioxidant Supplement on Lipid Profile, Occupational Fatigue, Work Stress, and Hair Cortisol in Administrative Workers with and Without Obesity: A Quasi-Experimental Pilot Study.

Healthcare (Basel, Switzerland)·2026
Same author

Label-free DNA-sensor modelling based on magnetic induction spectroscopy.

BioTechniques·2026
Same author

Variable shift work in family medicine residents is associated with a non-dipper pattern and reduced phase angle: possible adaptive blood pressure mechanisms and body composition imbalance.

Frontiers in cardiovascular medicine·2026
Same author

Micronuclei and Nuclear Abnormalities in Oral Mucosa as Indicators of Genotoxicity in Healthcare Professionals.

Toxics·2026
Same author

Enhancing Cytosolic Internalization of [<sup>177</sup>Lu]Lu-iPSMA in Prostate Cancer Cells: The Effect of Conjugating a GRP78 Inhibitor to the Radiotherapeutic Molecule.

International journal of molecular sciences·2025
Same author

Narrative Review: Gut Microbiota and Its Impact on α-syn Function in Parkinson's Disease.

MicrobiologyOpen·2025

Related Experiment Video

Updated: Jan 10, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.2K

Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.

Liliana Aranda-Lara1, Alondra Escudero-Castellanos1, Maydelid Trujillo-Nolasco1

  • 1Laboratorio de Investigación en Teranóstica, Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.

Pharmaceutics
|November 27, 2025
PubMed
Summary

Synthetic small interfering RNA (siRNA) formulations show promise for cancer therapy by silencing specific genes. Research focuses on developing stable, bioavailable siRNA delivery systems for personalized, genomics-guided cancer treatments.

Keywords:
cancer gene therapycell signaling targetssiRNA therapysiRNA transporter systems

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K

Related Experiment Videos

Last Updated: Jan 10, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.2K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K

Area of Science:

  • Oncology
  • Gene Therapy
  • Nanotechnology

Background:

  • Small interfering RNA (siRNA) is a key area of research in oncology.
  • While not yet FDA-approved for cancer, siRNA formulations demonstrate significant potential for tumor remission.

Purpose of the Study:

  • To review synthetic siRNA formulations for systemic cancer gene silencing.
  • To provide an overview of current siRNA-based cancer therapy designs.

Main Methods:

  • Conducted a literature search using keywords: "siRNA", "therapy", and "cancer".
  • Classified reviewed works by topic for comprehensive analysis.

Main Results:

  • Discusses siRNA design, chemical modifications for stability and bioavailability, and nanocarrier integration.
  • Examines various siRNA formulations, including conjugates and nanoparticles (organic, inorganic, hybrid), detailing their pros and cons.
  • Highlights the role of nanosystems in dual therapy and personalized cancer treatment.

Conclusions:

  • Personalized, genomics-guided cancer therapy is the future of oncology.
  • siRNA offers a flexible platform for targeting oncogenes in patient-specific treatments.